期刊文献+

念珠菌菌血症的易感因素分析及药敏检测 被引量:3

Predisposing factor analysis and susceptibility tests of candidemia
下载PDF
导出
摘要 目的探讨念珠菌菌血症的临床特点、菌种构成、危险因素及药敏情况,为临床治疗提供依据。方法收集我院2005年6月1日~2007年5月31日自血培养中分离出的92株念珠菌的菌种分布、药敏试验和危险因素等资料进行回顾性分析。结果菌种分布显示白念株菌感染为28.3%,除白念珠菌、光滑念珠菌、克柔念珠菌、热带念珠菌之外的其他念珠菌感染为45.6%。药敏试验显示耐氟康唑率达41.3%。感染的危险因素有免疫力低下、严重基础疾病、长时间应用广谱抗生素、介入诊治、气管切开及呼吸机的应用等,病死率超过55.4%。结论氟康唑不能作为所有酵母菌感染的首选药物。积极治疗原发病、加强病原学检测和药敏试验、及时作出早期诊断、严格掌握用药原则是降低病死率的关键。 Objective To study the clinical characteristics,stain distribution, predisposing factors and susceptibility tests of candidemia. Methods Ninty-two candida strains isolated from blood from June 1st 2005 to May 31th 2006 in our hospital was studied retrospectively. Results C. ablicans accounted for 28.3% of all strains and other uncommon candida 45.6%. The fluconazol resistance rate in candidemia was high(41.3%). The predisposing factors included immunodeficiency, serious underlaying diseases, long time administration of broad-spectrum antibiotics, interventional therapy, incision of trachea and mechanical ventilation. Overall mortality rate exceeded 55.4%. Conclusion Fluconazol was not the first choice of all kinds of yeast infections. Important measures to reduce mortality include curing the underlying diseases, emphasis on monoitoring fungal pathogen and susceptibility tests, early diagnosis and compliance medication principles.
出处 《中国真菌学杂志》 2007年第6期339-341,共3页 Chinese Journal of Mycology
关键词 血培养 念珠菌菌血症 危险因素 耐药性 hemoculture candidemia risk factor drug resistance
  • 相关文献

参考文献2

二级参考文献29

  • 1吴蓉,戴俊华,康向东,孙士康.2种药敏试验方法检测酵母菌对氟康唑敏感性的比较[J].检验医学,2004,19(4):295-297. 被引量:1
  • 2秦启贤.临床真菌学[M].上海:复旦大学出版社,2002.10.
  • 3Pfaller MA;Messer SA;Hollis R J.In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6 970 clinical isolates of Candida spp[J],2002(06).
  • 4Pfaller MA;Jones RN;Dogern GV.Bloodstream infections due to Candida species:SENTRY antimicrobial surveillance program in North America and Latin America,1997-1998[J],2000(03).
  • 5Abelson JA;Moore T;Bruckner D.Frequency of fungemia in hospitalized pediatric inpatients over 11 years at a tertiary care institution,2005(01).
  • 6Lin MY;Carmeli Y;Zumsteg J.Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia:a case-case-control study[J],2005(11).
  • 7Magill SS;Shields C;Sears CL.Triazole Cross-Risistance among Candida spp.:case report,occurrence among bloodstream isolates,and implications for antifungal therapy[J],2006(02).
  • 8Abi-Said D;Anaissie E;Uzun O.The epidemiology of hematogenous candidiasis caused by different Candida species[J],1997(06).
  • 9Godov P;Tiraboschi IN;Severo LC.Species distribution and antifungal susceptibility profile of Candida spp.Bloodstream isolates from Latin American hospitals,2003(03).
  • 10Yang Q;Wang L;Lu DN.Prophylactic vaccination with phage-displayed epitope of C.albicans elicits protective immune responses against systemic candidiasis in C57BL/6 mice[J],2005(31).

共引文献14

同被引文献39

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部